Browse Technologies

Displaying 11 - 20 of 44

New antibiotics against new targets in multi-drug resistant microorganisms

New everninomicin antibiotics including a potent bifunctional antibiotic natural product targeting two different and distant ribosomal sites are under development and can be readily produced using synthetic biology. Developing resistance to this bidentate antibiotic should be very difficult for pathogenic microorganisms.

Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Brian Bachmann, Emilianne Limbrick, Kasia Derewacz
Category:
Therapeutics
Field of Use:
Infectious Disease

New Drug for Blood Clot: FXII Inhibitors to Treat Thrombosis

Thrombosis is the formation of a blood clot inside a blood vessel, which may cause reduced blood flow to a tissue, or even tissue death. Thrombosis, inflammation, and infections are responsible for >70% of all human mortality. Thrombosis is also the major factor for heart disease and stroke. 500,000 die from thrombosis every year in Europe. Inhibitory treatment of these conditions may also improve the outcomes of several non-fatal diseases. Researchers from Vanderbilt University and Oregon Health & Science University have jointly discovered new monoclonal antibodies that potently inhibit the blood coagulation protein factor XII (FXII), a critical player in the pathway, and anticoagulate blood. This invention provides foundation for commercial development of anti-thrombotic drugs based on new molecular entities.

Licensing Contact

Mike Villalobos

615.322.6751

Inventors

David Gailani, Andras Gruber, Philberta Leung, Anton Matafonov
Category:
Therapeutics
Modality:
Antibody
Research Tool Type:
Assays/Screening

Vascular Restoration Therapy with Cell-Penetrating CRADD Protein

Vascular inflammation caused by metabolic, autoimmune, and microbial insults mediates cardiovascular diseases that include hypertension and atherosclerosis (heart attacks, strokes), systemic lupus, and giant cell arteritis. An estimated 35 million Americans have hypercholesterolemia, contributing to 500,000 deaths underlying heart attacks and strokes. In these diseases, metabolic, autoimmune, and microbial insults continually challenge blood and vascular cells by triggering signaling to the nucleus mediated by BCL10. Genetic ablation of BCL10 rescues animals from atherosclerosis, aortic aneurysms, and fatty liver and insulin resistance due to overnutrition. Intracellular therapy with CP-CRADD is designed to extinguish BCL10-mediated noxious signals to avert vascular inflammation and its life-threatening complications including ruptured aneurysms in aorta and brain.

Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Jack Hawiger, Lukasz Wylezinski, Huan Qiao, Ruth Ann Veach, Yan Liu
Category:
Therapeutics

Point of Care Rheological Assay for Sickle Cell Disease

Vanderbilt researchers have created a novel technology for the diagnosis and monitoring of disease states using the rheological properties of a blood sample with a lateral flow membrane.

Licensing Contact

Ashok Choudhury

615.322.2503

Inventors

Kevin Cyr, Christina Marasco, Jennifer Colby
Category:
Diagnostics Medical Devices

I-Wire: A Biotension Measurement Device for Tissue Engineering and Pharmacology

Vanderbilt researchers have developed an integrated system ("I-Wire") for the growth of miniature, engineered 3D cardiac or other muscle or connective tissues and their active and passive mechanical characterization. The system utilizes an inverted microscope to measure the strain when the tissue constructs are laterally displaced using a calibrated flexible cantilevered probe.

Licensing Contact

Ashok Choudhury

615.322.2503

Inventors

John Wikswo, Jr., Philip Samson, Jeffrey Davidson, Stephen Koch, Veniamin Sidorov
Category:
Diagnostics Microfluidics

Breast Tumor Margin Detection System Using Spatially Offset Raman Spectroscopy

Vanderbilt University researchers have developed a technology that uses spatially offset Raman spectroscopy to obtain depth-resolved information from the margins of tumors. This helps to determine positive or negative tumor margins in applications such as breast lumpectomy, and the technology is currently being investigated for breast cancer margin detection.

Licensing Contact

Ashok Choudhury

615.322.2503

Inventors

Anita Mahadevan-Jansen, Quyen Nguyen, Matthew Keller, Xiaohong Bi, Mark Kelley, Zain Gowani, Ginger Holt, Isaac Pence
Category:
Diagnostics Medical Devices Medical Imaging

Low-cost, Normally Closed Microfluidic Valve

Vanderbilt researchers have developed a normally closed valve that is able to provide selective movement of small fluid quantities in a microfluidic device. The present microfluidic valve can be actuated using a simple rotating drivehead and mechanical support, greatly simplifying the valve design.

Licensing Contact

Ashok Choudhury

615.322.2503

Inventors

John Wikswo, Jr., Dmitry Markov, Lisa McCawley, John McLean, David Cliffel, Randy Reiserer, Philip Samson, Frank Block, Jennifer McKenzie, William Matloff, Hunter Tidwell, Joseph Scherrer, Erik Werner
Category:
Diagnostics Microfluidics

New Molecules Clear Chronic Infections by Disrupting Bacterial Energy Production Pathways

New compounds developed at Vanderbilt demonstrate a unique mechanism of broad spectrum activity to stymy antibacterial resistance. The compounds are particularly useful in chronic infections where long term antibiotic therapy fails, because it specifically kills "small colony variants" -- the bacteria that have developed resistance mechanisms. These compounds show promise in treating Methicillin-resistant S. aureus (MRSA), Bacillus anthracis (anthrax), and in overcoming difficult-to-treat infections in bone in cystic fibrosis patients. These compounds could be combined with new (and old) antimicrobial drugs to outwit resistant bacterial infections.

Licensing Contact

Karen Rufus

615.322.4295

Inventors

Eric Skaar, Laura Mike, Gary Sulikowski, Alex Waterson, Paul Reid
Category:
Therapeutics

Oral administration of levocarnitine for treating Sjögren's Syndrome-associated dry eye

Sjögren's syndrome (SjS) is a common and debilitating autoimmune disease, causing dry eye symptoms ranging from discomfort to dysfunction. Vanderbilt researchers have identified orally administered levocarnitine as a novel potential therapeutic for treating this condition.

Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Jill Pulley, Jillian Rhoads, Leslie Crofford
Category:
Natural Products Therapeutics
Field of Use:
Opthamology

Anti-inflammatory microparticles for sustained ocular drug delivery

Vanderbilt researchers have developed an injectable drug delivery vehicle using microparticles (MPs) that not only provide sustained cargo delivery over extended time but also play a therapeutic role themselves in reducing inflammation. This drug delivery platform can be used in treating ocular diseases such as glaucoma and traumatic optic neuropathy, as well as other inflammatory diseases throughout the body like peripheral arterial disease and osteoarthritis.

Licensing Contact

Taylor Jordan

615.936.7505

Inventors

Craig Duvall, Carlisle DeJulius, Richard d'Arcy, Tonia Rex, Sarah Naguib
Category:
Therapeutics
Field of Use:
Inflammatory/Immune/Wound Repair Opthamology